Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
700 participants
INTERVENTIONAL
2003-10-31
2006-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
SINGLE_GROUP
PREVENTION
NONE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Implanted Device
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
If patient has had an electrophysiology test in the past, and has sustained inducible VT \<180 bpm.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Medtronic
INDUSTRY
Medtronic Cardiac Rhythm and Heart Failure
INDUSTRY
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Bruce Wilkoff, M.D
Role: PRINCIPAL_INVESTIGATOR
The Cleveland Clinic
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Birmingham, Alabama, United States
Mesa, Arizona, United States
Phoenix, Arizona, United States
San Diego, California, United States
San Pablo, California, United States
Newark, Delaware, United States
Fort Lauderdale, Florida, United States
Jacksonville, Florida, United States
Merrit Island, Florida, United States
Columbus, Georgia, United States
Maywood, Illinois, United States
Rockford, Illinois, United States
Topeka, Kansas, United States
Portland, Maine, United States
Silver Spring, Maryland, United States
Takoma Park, Maryland, United States
Boston, Massachusetts, United States
Royal Oak, Michigan, United States
Minneapolis, Minnesota, United States
Paterson, New Jersey, United States
Buffalo, New York, United States
New York, New York, United States
Columbus, Ohio, United States
Elyria, Ohio, United States
Bethlehem, Pennsylvania, United States
Lancaster, Pennsylvania, United States
Columbia, South Carolina, United States
Nashville, Tennessee, United States
Amarillo, Texas, United States
Kirkland, Washington, United States
Morgantown, West Virginia, United States
San Juan, , Puerto Rico
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
van Gelder IC, Phan HM, Wilkoff BL, Brown ML, Rogers T, Peterson BJ, Birgersdotter-Green UM. Prognostic significance of atrial arrhythmias in a primary prevention ICD population. Pacing Clin Electrophysiol. 2011 Sep;34(9):1070-9. doi: 10.1111/j.1540-8159.2011.03124.x. Epub 2011 May 23.
Wilkoff BL, Williamson BD, Stern RS, Moore SL, Lu F, Lee SW, Birgersdotter-Green UM, Wathen MS, Van Gelder IC, Heubner BM, Brown ML, Holloman KK; PREPARE Study Investigators. Strategic programming of detection and therapy parameters in implantable cardioverter-defibrillators reduces shocks in primary prevention patients: results from the PREPARE (Primary Prevention Parameters Evaluation) study. J Am Coll Cardiol. 2008 Aug 12;52(7):541-50. doi: 10.1016/j.jacc.2008.05.011.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
223
Identifier Type: -
Identifier Source: org_study_id